Company & Sponsor Intelligence
Affiris AG
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials3
Recruiting0
Completed2
Countries1
Therapeutic footprint
alzheimers
Indexed studies
NCT00633841Tolerability and Safety of Subcutaneous Administration of AFFITOPE AD02 in Mild to Moderate Alzheimer's Disease
alzheimers · AustriaPHASE1
alzheimers · AustriaPHASE1
NCT00495417Tolerability and Safety of Subcutaneous Administration of Affitope AD01 in Mild to Moderate Alzheimer's Disease
alzheimers · AustriaPHASE1
alzheimers · AustriaPHASE1
NCT02008513Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006
alzheimers · AustriaPHASE2
alzheimers · AustriaPHASE2
Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →